Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 327Neoplasm Metastasis 31Advanced Breast Cancer 19Neoplasms 17Ovarian Neoplasms 11Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Breast Diseases 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms by Site 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Recurrence 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Breast Neoplasm Female 3Uterine Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2Hyperglycemia 2HER2-positive Metastatic Breast Cancer 2HER2-positive Breast Cancer 2

Interventions

Fulvestrant 2vistusertib 1proto-oncogene protein c-fes-fps 1capivasertib 1Transurethral Resection of Bladder 1Hydroxychloroquine 1Everolimus 1Estrogens 1Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Estrogen Receptor Positive Breast Cancer × Fulvestrant × Breast × Clear all
NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

NCT02216786 2024-12-02

MANTA

Queen Mary University of London

Phase 2 Completed
333 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡